HomeComparePARD vs KMB

PARD vs KMB: Dividend Comparison 2026

PARD yields 2000000.00% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PARD wins by $1.6247481716182984e+23M in total portfolio value
10 years
PARD
PARD
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.6247481716182984e+23M
Annual income
$147,608,011,402,949,780,000,000,000,000.00
Full PARD calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — PARD vs KMB

📍 PARD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPARDKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PARD + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PARD pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PARD
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$125,466,809,692,507,310,000,000,000,000.00/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, PARD beats the other by $125,466,809,692,507,310,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PARD + KMB for your $10,000?

PARD: 50%KMB: 50%
100% KMB50/50100% PARD
Portfolio after 10yr
$8.123740858091492e+22M
Annual income
$73,804,005,701,474,890,000,000,000,000.00/yr
Blended yield
90.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

PARD
No analyst data
Altman Z
-88.2
Piotroski
2/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PARD buys
0
KMB buys
0
No recent congressional trades found for PARD or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPARDKMB
Forward yield2000000.00%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%17%
Portfolio after 10y$1.6247481716182984e+23M$45.9K
Annual income after 10y$147,608,011,402,949,780,000,000,000,000.00$5,222.34
Total dividends collected$1.6146053563276882e+23M$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: PARD vs KMB ($10,000, DRIP)

YearPARD PortfolioPARD Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,314$614.45+$100.00MPARD
2$467,446,731,075$467,339,719,626.17$12,867$760.19+$467446.72MPARD
3$1,021,215,363,816,662$1,020,715,195,814,411.90$14,713$945.27+$1021215363.80MPARD
4$1,043,112,617,104,109,200$1,042,019,916,664,825,300.00$16,924$1,181.90+$1043112617104.09MPARD
5$498,482,143,759,731,400,000$497,366,013,259,430,040,000.00$19,596$1,486.64+$498482143759731.38MPARD
6$111,599,275,650,097,780,000,000$111,065,899,756,274,860,000,000.00$22,850$1,882.16+$111599275650097776.00MPARD
7$11,738,678,336,351,557,000,000,000$11,619,267,111,405,953,000,000,000.00$26,849$2,399.80+$11738678336351557632.00MPARD
8$583,674,362,697,175,100,000,000,000$571,113,976,877,278,900,000,000,000.00$31,812$3,083.36+$583674362697175072768.00MPARD
9$13,894,210,989,607,547,000,000,000,000$13,269,679,421,521,570,000,000,000,000.00$38,033$3,994.72+$1.3894210989607547e+22MPARD
10$162,474,817,161,829,840,000,000,000,000$147,608,011,402,949,780,000,000,000,000.00$45,918$5,222.34+$1.6247481716182984e+23MPARD

PARD vs KMB: Complete Analysis 2026

PARDStock

Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.

Full PARD Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this PARD vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PARD vs SCHDPARD vs JEPIPARD vs OPARD vs KOPARD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.